Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Molecular anomalies in malignant hemopathies]

L Mauvieux, E Macintyre

    Presse Medicale (Paris, France : 1983)
    |June 21, 1997
    PubMed
    Summary

    Molecular anomalies in blood cancers, like leukemia and lymphoma, involve gene rearrangements that can lead to either overexpressed normal proteins or abnormal fusion proteins, serving as crucial tumor-specific markers for diagnosis and treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Waiting in Pain II: An Updated Analysis of the Multidisciplinary Staffing Levels and Clinical Activity in Australian Specialist Persistent Pain Services.

    The journal of pain·2023
    Same author

    ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

    Annals of oncology : official journal of the European Society for Medical Oncology·2023
    Same author

    Osteoarthritis consumers as co-researchers: identifying consumer insights to improve osteoarthritis management by co-designing translational research solutions.

    Osteoarthritis and cartilage·2023
    Same author

    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.

    British journal of haematology·2023
    Same author

    Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

    Nature medicine·2022
    Same author

    Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

    Nature medicine·2022

    Area of Science:

    • Hematology
    • Oncology
    • Molecular Biology

    Background:

    • Malignant hematologic diseases provide key insights into oncogenesis due to accessible hematopoietic cells.
    • Genomic DNA rearrangements in lymphoid tumors can juxtapose proto-oncogenes with immunoglobulin or T-cell receptor regulatory sequences, leading to overexpression of normal proteins.

    Discussion:

    • Quantitative anomalies, like BCL2 overexpression in follicular lymphomas, inhibit apoptosis and contribute to immortalization.
    • Qualitative anomalies in myeloid hemopathies result from gene fusions producing oncogenic proteins.
    • These anomalies affect genes controlling cell cycle, differentiation, and apoptosis, including transcription factors and signal transduction molecules.

    Key Insights:

    • Molecular anomalies are found in ~30% of acute leukemia and up to 75% of non-Hodgkin lymphomas.
    • Analysis of immunoglobulin heavy chain junction fragments serves as a specific marker for B or T-cell clones.
    • BCR-ABL transcript detection aids in diagnosing primary thrombocythemia and myeloproliferative syndromes.

    Outlook:

    • Molecular markers in hematologic malignancies offer prognostic value, enabling patient stratification and tailored therapies.
    • These molecular anomalies represent highly specific tumor markers for improved diagnostics and treatment strategies.

    Related Experiment Videos